#Veeva Systems #Denmark #Copenhagen #Veeva Falcon #Vault AI

Veeva Summit Reveals the Future of Biopharma Technology

The Veeva R&D and Quality Summit Europe took place from May 28 to 29, 2026, in Copenhagen, Denmark, bringing together over 2,000 industry leaders. This year’s summit was particularly significant as it highlighted Veeva Systems' latest innovations, including the Veeva Falcon agentic labor platform and advancements in Vault AI technology.

During the event, major players in the life sciences sector such as AOP Health, Boehringer Ingelheim, GSK, and Roche converged to share insights and strategies aimed at enhancing operational efficiency within the industry. Attendees showcased how they have successfully streamlined their processes to adapt to the evolving landscape, emphasizing the growing importance of AI integration.

Innovations Unveiled at the Summit

Veeva introduced the Vault AI Agents that are already available, along with a preview of the upcoming Vault AI functionality set to roll out across all Vault applications starting August 2026. In particular, the Veeva Falcon platform aims to revolutionize agentic labor by minimizing operational costs and accelerating timelines, all while ensuring compliance in the drug development process. Falcon will serve as a pioneering tool for early adopters, who will utilize its capabilities for optimizing trial master file document intake and conducting thorough quality control.

The summit featured over 100 sessions discussing various aspects of the industry. Among the topics addressed was the role of data connectivity in accelerating development practices. AOP Health’s successful strategies for integrating research and development with data solutions on the Veeva Industry Cloud were shared as a best practice, showcasing their swift transition from development to delivery.

Streamlining Clinical Operations

Boehringer Ingelheim presented its comprehensive approach to clinical operations, demonstrating how unified data can substantially enhance collaboration with both sites and patients. GSK’s focus was on standardizing engagement with clinical sites to ensure quicker activation and heightened performance, which is crucial in today’s fast-paced environment. Additionally, Novo Nordisk and Syneos Health Consulting discussed the importance of effective data ownership and the need for seamless connections between Electronic Data Capture (EDC) systems and clinical databases to foster clinical efficiency.

Enhancing Quality and Compliance

In terms of modernizing quality and compliance practices, several companies, including Haleon and Sanofi, discussed their preparations for incorporating agentic AI into their quality assurance processes. The emphasis on efficiency and the accurate management of global data was underscored by Novo Nordisk’s initiatives on simplifying pharmacovigilance to achieve better outcomes.

Rick van Mol, Senior Vice President at Veeva Development Cloud, expressed optimism about the collaborative spirit generated at the summit. He stated, “The ideas shared and connections made at Veeva Summit will extend far beyond the event to move the industry toward an agentic future.” The integration of Vault AI and the Veeva Falcon platform is anticipated to play a pivotal role in enhancing life sciences efficiency and accelerating the pace of innovation.

Conclusion

The Veeva R&D and Quality Summit showcased not just the new tools available but also the collaborative efforts among leading biopharma companies to streamline operations and integrate advanced technologies. As the industry moves toward a future enhanced by AI, platforms like Veeva Falcon promise to reshape how drug development and compliance processes are managed. For detailed insights and session replays, visit Veeva Connect.

In conclusion, the advancements presented at the summit mark a watershed moment for the life sciences sector, setting the stage for a future built on collaboration, efficiency, and innovation.